hotspot -WSS

hotspot

author：explore 2025-09-06 04:50:45 - browse：12

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Grail spinoff by Illumina should end disastrous merger attempt

knowledge

WSS

The science behind Janet Jackson's pregnancy at 49

Why health care costs have stayed mostly flat since 2010

Hospitals owned by private equity see complications spike 25%

The story of mRNA: From a loose idea to a tool that may help curb Covid

Why health records don't always know when patients are dead

Carvykti CAR

focus

hotspot

knowledge

Apple is now the first public company to be valued at $3 trillion

In areas with more Black doctors, Black people live longer

As demand for Covid shots wanes, Moderna seeks its next success

Virtual care provider acquires bankrupt Pear's prescription apps

DIEP, the 'gold standard' of breast reconstruction, is under threat

Colonoscopy at 40? Study finds a possible benefit

Heart attack and stroke risk calculators need revising

Medicare drug price negotiation hasn't dried up venture capital

Jerome Adams on the need for new antivirals for Covid

Virtual care provider acquires bankrupt Pear's prescription apps

explore

Medicare Advantage beneficiaries sue Humana over algorithm use

Why health care costs have stayed mostly flat since 2010

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Bristol Myers buys into radiopharmaceuticals with RayzeBio

3 hurdles to bringing medical devices to the U.S. market

explore

knowledge

explore

focus